|
|
K3-SPG |
|
Vaxjo ID |
345 |
|
Vaccine Adjuvant Name |
K3-SPG |
|
Adjuvant VO ID |
VO_0005641
|
|
Description |
K3-SPG is a second-generation TLR9 agonist, a humanized CpG DNA (K3) complexed with schizophyllan (SPG), and a nonagonistic Dectin-1 ligand. It is an antigen-free, plasmacytoid dendritic cell-targeting immunotherapy. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
K3-SPG was previously shown to act as a potent monoimmunotherapeutic agent against established tumors in mice in vivo |
|
Structure |
It is a complex of humanized CpG DNA (K3) and schizophyllan (SPG). |
|
Preparation |
It is formed by complexing humanized CpG DNA (K3) with schizophyllan (SPG). |
|
Dosage |
2 mg was injected subcutaneously (s.c.) or intravenously (i.v.) in cynomolgus macaques. |
|
Function |
We recently developed a second-generation TLR9 agonist, a humanized CpG DNA (K3) complexed with schizophyllan (SPG), K3-SPG, a nonagonistic Dectin-1 ligand |
|
Safety |
A single injection of 2 mg K3-SPG induced mild systemic inflammation, but the levels of proinflammatory serum cytokines and circulating neutrophil influx were lower than those induced by the same dose of polyinosinic-polycytidylic acid. |
| References |
Masuta et al., 2018: Masuta Y, Yamamoto T, Natsume-Kitatani Y, Kanuma T, Moriishi E, Kobiyama K, Mizuguchi K, Yasutomi Y, Ishii KJ. An Antigen-Free, Plasmacytoid Dendritic Cell-Targeting Immunotherapy To Bolster Memory CD8(+) T Cells in Nonhuman Primates. Journal of immunology (Baltimore, Md. : 1950). 2018; 200(6); 2067-2075. [PubMed: 29431693].
|
|
